Amendment No. 1 to Schedule 13D for CG Oncology, Inc.

This filing represents Amendment No. 1 to the Schedule 13D previously filed by Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Dr. Brian Liu regarding their holdings in CG Oncology, Inc. The amendment reflects an internal restructuring into a master-feeder structure, where Seven Fleet Partners LP contributed all of its 1,515,151 shares to Seven Fleet Master Fund LP on October 6, 2025. This restructuring changed the identity of the reporting persons and corrected the initial Schedule 13D's identification of the investment manager. The filing also includes an Amended and Restated Joint Filing Agreement dated October 28, 2025. The Reporting Persons collectively beneficially own approximately 1.9% to 2.0% of the outstanding shares of CG Oncology, Inc.